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Abstract
Cell replacement and regenerative therapy using embryonic stem cell-derived material holds promise for the treatment
of several pathologies. However, the safety of this approach is of prime importance given the teratogenic potential of
residual stem cells, if present in the differentiated cell product. Using the example of embryonic stem cell-derived
retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration, we present a novel
strategy for ensuring the absence of stem cells in the RPE population. Based on an unbiased screening approach,
we identify and validate the expression of CD59, a cell surface marker expressed on RPE but absent on stem cells.
We further demonstrate that flow sorting on the basis of CD59 expression can effectively purify RPE and deplete
stem cells, resulting in a population free from stem cell impurity. This purification helps to ensure removal of
stem cells and hence increases the safety of cells that may be used for clinical transplantation. This strategy can
potentially be applied to other pluripotent stem cell-derived material and help mitigate concerns of using such
cells for therapy.
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Introduction
Safety is a primary consideration for any clinical programme.
Differentiated cell products generated from human embry-
onic stem cells (hESCs) or human induced pluripotent stem
cells (hiPSCs) pose particular challenges because there is a
risk that residual pluripotent stem cells could give rise to
teratomas upon transplantation [1, 2]. However, the
therapeutic promise of using stem cell-derived material
cannot be overlooked. For instance, the transplantation of
pluripotent-derived retinal pigment epithelium (RPE) in pa-
tients suffering from age-related macular degeneration
(AMD) has the potential to halt visual decline and restore
visual function. This approach has been under investigation
in both pre-clinical and clinical settings with promising
results [3, 4].
AMD is a leading cause of irreversible vision loss among
the older population in the developed world [5]. AMD
affects RPE cells, which are situated as a monolayer beneath
the photoreceptors and perform several important functions
to maintain the visual cycle; for example, metabolism and
storage of retinoid, phagocytosis of rod outer segments, ab-
sorption of scattered light, barrier activity and ion transport
[6]. Degeneration of RPE in AMD results in subsequent
loss of photoreceptors leading to loss of vision. Several
methods for generating mature and functional RPE from
hESC and hiPSC have been described in the literature
(reviewed in [7]). Techniques such as quantitative PCR,
flow cytometry and in-vivo teratoma formation are com-
monly employed to show that the RPE population is free
from hESC or hiPSC [8]. In this report, we investigate a
strategy that enables us to select RPE cells and purify them
from any potential stem cell contaminant, thereby ensuring
safety for clinical application. Using an unbiased screening
approach we identify CD59, a cell surface marker that is
expressed on RPE but is absent on hESC. CD59, also
known as protectin, is an 18–21 kDa glycoprotein which
anchors to cell membranes by a GPI anchor [9]. It inhibits
the membrane attack complex (MAC) which mediates cell
lysis and inflammation and is formed upon complement
activation [10]. Interestingly, MAC formation correlates
with AMD severity and its negative regulation by CD59 is
under investigation for AMD therapy [11, 12]. CD59 has
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been shown previously to be expressed in RPE cells in both
human and rodent models of retinal physiology [13–18].
We show that sorting cells on the basis of CD59 expres-
sion positively selects RPE cells and concomitantly removes
pluripotent stem cells from a mixed population, thereby
resulting in purification. This approach can potentially be
applied to diverse cell types and can help to ensure safety
of stem cell-derived cells in general or be used to generate
homogeneous cell populations for research and in-vitro
disease modelling.
Materials and methods
Directed differentiation of pluripotent stem cells towards RPE
The protocol for differentiation of hESC or hiPSC towards
RPE has been described elsewhere [19]. Briefly, pluripo-
tent stem cells are seeded on Matrigel (Corning) coated
surfaces and on day 2 of culture the growth medium
(KnockOut DMEM medium (Gibco) supplemented with
20 % KnockOut Serum Replacement Xeno-Free (Gibco),
1 % β-mercaptoethanol (Sigma), 1 % GlutaMax (Gibco)
and 1 % non-essential amino acid solution (Gibco)) is
supplemented with two inhibitors, 1 μM LDN-193189
(Stemgent) and 10 μM SB-431542 (Sigma), for a period
of 4 days. This is followed by treatment of cells with
100 ng/ml BMP 4/7 (R&D Systems) for a period of
3 days. At this stage, cells are dissociated and replated
in the presence of 100 ng/ml Activin A (R&D Systems).
After a period of 19 days, cells are again dissociated
and replated in medium without any supplements for
14 days. By this stage of the protocol, RPE cells with
close to 100 % purity are generated. Interested readers
can refer to a patent (US 2015/0159134 A1) that also
describes the protocol in greater detail. In this report,
we used the pluripotent stem cell line SHEF1 for differ-
entiation towards RPE.
Imaging and flow cytometry
RPE cells derived by directed differentiation were plated at
a density of 100,000 cells/cm2 on 384-well plates coated
with Matrigel (BD Biosciences). Cells were cultured for
7 days before performing a screen for cell surface protein
expression using the BD Lyoplate™ Human Cell Surface
Marker Screening Panel (BD Biosciences). The morphology
of cells used for secreening is shown in Additional file 1:
Figure S1. The manufacturer’s recommendations for bioi-
maging were followed for screening cells. For flow cytome-
try, cells were stained with the Live/Dead fixable green
dead cell stain kit (Invitrogen). Following this, cells were
fixed with 1 % PFA and washed three times with PBS.
Centrifugation was performed at 300 × g for 5 minutes.
Cells were resuspended to approximately 1 × 106 cells/
100 μl in PBS containing 2 % BSA. Cells were stained with
PE-conjugated or APC-conjugated antibodies (BD Phar-
mingen) using 20 μl antibody per 100 μl of experimental
sample. Samples were incubated for 30 minutes protected
from light at room temperature, and then washed twice
before being resuspended in 150 μl PBS containing 2 %
BSA for analysis on the Accuri C6 flow cytometer. Negative
controls consisting of unstained cells and cells stained with
the isotype control (BD Pharmingen) were performed in
parallel. Flow cytometry analysis was performed by gating
out the debris and doublets and selecting live. Sorting was
performed under sterile conditions using an inFlux v7
cytometer housed in a biological safety cabinet. The sorting
efficiency (i.e. number of positive events detected by the
cytometer compared with the number of events around
which a sort decision was made) was between 80 and 85 %.
RNA extraction, cDNA synthesis and quantitative PCR
Total RNA was extracted from RPE cells using the RNeasy
Mini or Micro Kit (Qiagen) with on-column DNase diges-
tion. cDNA was synthesized using the High Capacity
cDNA Synthesis kit (Applied Biosystems). Individual gene
expression was assessed using predesigned Taqman assays
(Applied Biosystems) and the reactions were carried out
on the CFX96 iCycler platform (Biorad). Gene expression
in all instances was quantified by the relative quantifica-
tion method of 2–ΔΔCt and normalized to geometric
means of at least two housekeeping genes.
Results
Screening to identify cell surface markers expressed on
RPE cells
To identify a unique cell surface marker expressed on
RPE cells, we performed an unbiased screen for cell sur-
face markers that were present exclusively on mature
RPE but not on hESC or progenitor cells to enable
effective depletion of these impurities by cell sorting. For
this approach, we made use of the BD Lyoplate™ Human
Cell Surface Marker Screening Panel consisting of a
library of antibodies targeting a range of cell surface
proteins, glycoproteins and glycosphingolipids together
with relevant isotype controls. Immunocytochemistry
was performed in live cells, to prevent fixation-induced
artefacts, and under non-permeabilized conditions so
that only proteins expressed on the cell surface could be
visualized. Using this approach, we found 13 ‘hits’ or
markers staining positively on RPE cells above back-
ground levels using negative controls, for example iso-
type matched antibodies and unstained cells (Fig 1a). An
example of immunostaining of a positive hit, CD59, is
shown in Fig. 1b. Next, we used flow cytometry to verify
expression of markers identified by immunocytochem-
istry because it can be more easily adapted to cell sorting
and purification applications. Of the 13 markers tested,
four markers were found to be expressed at low levels
(<20 %) whereas the remaining nine markers had >90 %
positive expression compared with a range of isotype
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controls (Fig. 1c). We excluded markers that are known
to be ubiquitously expressed on all nucleated cells (e.g.
HLA) or on tumour cells (e.g. CD47) and focused our
attention on five markers (CD57, CD59, CD81, CD164
and CD98) for further interrogation.
CD59 is expressed on RPE and not on hESC
For application of cell sorting to purify RPE away from
any residual hESC, the cell surface marker of choice
should be expressed on RPE but not on stem cells.
Therefore, we next tested whether the shortlisted
markers fulfilled this criterion. The hESC line SHEF1
together with RPE derived from it were tested in parallel
for expression of markers of interest by flow cytometry.
Out of the markers tested, only CD59 was found to be
expressed on RPE but at very low levels on hESC when
compared with the corresponding isotype control
(Fig. 2a, Additional file 2: Figure S2). Furthermore, neg-
ligible expression of CD59 was detected during initial
stages of differentiation where the hESC are not yet
committed to an RPE fate (Fig 2b, Additional file 3:
Figure S3). This supports the notion that sorting based
on CD59 expression could purify RPE away from stem
or progenitor cells.
In order to further explore specificity of CD59 expres-
sion on RPE compared with hESC, we performed a
spiking experiment where a cell suspension consisting of
known numbers of hESCs mixed with known numbers
of RPE cells was created. Flow cytometry was used to
detect CD59 expression in this mixed cell population
and TRA-1-60 expression was used to identify stem
cells. We found the CD59-positive staining to track
closely with the proportion of RPE cells present in the
cell suspension (Fig 2c, Additional file 4: Figure S4). This
Fig. 1 Screening for cell surface markers expressed on RPE cells. a Representative image showing results of screening for identification of cell
surface markers expressed on RPE. Overview of DAPI (left) and antibody (right) specific staining in a 384-well plate. Green boxes indicate positive
staining with a cell surface marker, red boxes indicate isotype controls and yellow boxes indicate unstained cells. b Representative image showing
a magnified view of a well staining positive with an antibody against CD59 (red) compared with background staining using isotype control. Nuclei
are stained with DAPI (blue). Scale bar = 150 μm. c % positive expression of indicated antigen in RPE cells as determined by flow cytometry. DAPI
4′,6-diamidino-2-phenylindole (Colour figure online)
Choudhary and Whiting Stem Cell Research & Therapy  (2016) 7:127 Page 3 of 8
confirms that CD59 expression can be used to distin-
guish between RPE and hESC and can potentially be
used to remove stem cells from RPE cultures.
Negative selection for CD59 as a strategy for removal of
stem cells and purification of viable RPE
In order to demonstrate a proof of principle supporting
sorting on the basis of CD59 expression to deplete stem
cells and purify RPE, we created a cell population
consisting of hESCs and RPE mixed in a 1:1 ratio. Flow
cytometry was used to collect the population staining
positive for CD59 separately from the population stain-
ing negative for CD59 expression (Fig 3a, Additional file
5: Figure S5). Encouragingly, the cell pellets of the
CD59-positive fraction displayed pigmentation consist-
ent with the presence of RPE whereas the CD59-
negative cells were non-pigmented, indicative of hESCs
(Fig 3b). Quantitative PCR was used to analyse the ex-
pression of stem and RPE markers in the two fractions.
Consistent with the visual pigmentation, hESC markers
(Pou5f1, Nanog, Lin28) were found to be expressed in
the CD59-negative fraction whereas RPE markers (Best,
Rlbp1, Pmel) were present in the CD59-positive fraction
(Fig 3c). The sorted CD59-positive cells could be main-
tained in culture for an extended period and cells
adopted a typical RPE morphology (Fig 3d, left). In con-
trast, the CD59-negative fraction seeded at the same
density does not develop into a cellular monolayer
under the same culture conditions (Fig 3d, right).
Furthermore, the sorted cells did not retain the anti-
CD59 antibody used for initial sorting because there
was no PE signal detectable in the cells after 45 days
in culture (Fig 3e). This suggests that RPE purified
through this approach would have a normal cell sur-
face profile with no exogenous antibody present
which might interfere with function.
We further performed quantitative PCR analysis to
check expression of CD59 transcript in RPE derived
from different sources; for example, the directed differ-
entiation approach used in this study, spontaneous dif-
ferentiation described previously [20] or in foetal RPE.
This RPE CD59 expression was compared with expres-
sion in a variety of human pluripotent cell lines ranging
from hESC lines (e.g. SHEF1, H9) and hiPSC lines from
a variety of donors. RPE markers Rlbp1 and Best1 and
stem cell markers Pou5f1 and Lin28 were used to distin-
guish between the identity of RPE and stem cells. On
average, the expression of CD59 was about 6-fold higher
in RPE cells compared with pluripotent cells (Fig 4), in-
dicating that sorting for CD59 could be broadly applied
for purification of RPE cells and removal of stem cell im-
purity irrespective of the type of pluripotent stem cell
line used for RPE derivation. Taken together, these data
are in keeping with the hypothesis that such sorting
Fig. 2 Identification and validation of CD59 expression on RPE cells. a % positive expression of indicated antigens in hESCs and RPE cells as
determined by flow cytometry. PE-conjugated or APC-conjugated antibodies together with the respective isotypes were used. b % positive CD59
expression at different stages of the RPE differentiation protocol. c Results of a spiking experiment where different ratios of hESCs and RPE were
mixed together and expression of CD59 and the stem cell marker TRA-1-60 was determined by flow cytometry. hESC human embryonic stem cell,
RPE retinal pigment epithelium
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approaches can be undertaken to effectively purify stem
cells during a differentiation paradigm.
Discussion
Recent breakthroughs in stem cell biology, especially the
development and application of induced pluripotent
stem cell techniques, have generated tremendous enthu-
siasm and efforts to explore the therapeutic potential of
stem cells in regenerative medicine. The use of stem
cell-derived RPE for the treatment of AMD is under
clinical investigation because there are several advan-
tages of targeting the eye as an organ for stem cell-based
therapies, for example ease of administration route, size,
potential immune privilege, separation from systemic
circulation and so forth [21]. However, in applications
based on hESC or hiPSC, the safety of the therapeutic
product is of prime importance given that residual
stem cells may have the capacity of unlimited prolif-
eration and self-renewal resulting in teratomas or
teratocarcinomas that can potentially be highly malig-
nant [2].
Current protocols for RPE generation from hESC or
hiPSC rely on the differentiation process together with
culture conditions; for example, use of culture medium
and extracellular matrices that would not support stem
cell growth to prevent the presence of residual stem cells
Fig. 3 Sorting for CD59 for RPE purification and stem cell removal. a Use of flow cytometry-based sorting to collect the population expressing CD59 (CD59+)
separately from the population not expressing CD59 (CD59–) in a 1:1 mixture of hESCs and RPE cells. b Representative image showing pigmentation in the
cell pellets obtained from the CD59+ and CD59– fractions. c Quantitative PCR to measure expression of pluripotency (top) and RPE markers
(bottom) in CD59+ and CD59– fractions. The pre-sorted cell suspension is used for comparison. ACT and GAPDH were used as housekeeping
genes (n = 4, ± SD). d Representative bright-field images showing the cobblestone architecture of CD59+ and CD59– fractions seeded at a
density of 78,000 cells/cm2 and cultured for a period of 45 days post sorting. Scale bar = 200 μm. e No CD59-PE fluorescence can be seen in cells
described in d as compared with cells freshly stained for CD59 used as a positive control (CD59 pos. ctrl)
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in a differentiated RPE population. Furthermore, most
cell purifications performed for clinical cell therapy
utilize antibody-coupled magnetic bead-based sorting,
referred to as magnetic-activated cell sorting (MACS)
[22, 23], a population-based method which has a faster
purification time compared with FACS. However, the
method is limited by a lower efficiency of sorting and
does not allow for analysis of individual cells. This is a
disadvantage particularly for hESC or hiPSC applications
because the benefit of single cell analysis allows a better
chance for identifying and isolating stem cells that may
be present in a minority.
In this report, we aimed to explore a novel strategy for
ensuring purity of a RPE population by identifying and
sorting on the basis of a specific cell surface marker that
would be expressed on RPE but not on stem cells. We
used an unbiased screening approach to identify CD59
expression on RPE but at negligible levels on stem cells
and further demonstrated that sorting for CD59 expres-
sion can effectively purify RPE and deplete pluripotent
stem cells from a mixed population. CD59 is involved in
suppression of the complement pathway and contributes
towards the potential RPE-dependent immune privilege
associated with the eye [18]. CD59 identification is
therefore consistent with the functional attributes of
RPE. We have not formally ruled out that CD59 is
expressed exclusively on RPE and not on other cell types
generated during differentiation. However, because sort-
ing for CD59 will lead to removal of stem cells, it is still
a beneficial step to be included in the differentiation
protocol to ensure that residual stem cells are removed
effectively. Further work is also needed to demonstrate
that CD59-positive cells do not have any features of
pluripotency, for example with the use of teratoma and
colony formation assays, embryoid body formation and al-
kaline phosphatase staining. It will also be interesting to
explore strategies based on negative sorting for RPE puri-
fication. For instance, pluripotent stem cell specific
markers such as SSEA3 or TRA-1-60 could be used to
label residual stem cells and the negative fraction would
potentially be free of pluripotent stem cells. However,
there are technical challenges around the detection of
such potentially rare events which require a high signal-
to-noise ratio and a large sample number to be accurate.
It is noteworthy that the CD59 transcript can be de-
tected in pluripotent stem cells, albeit at a level that is
Fig. 4 Comparison of CD59 expression in RPE vs pluripotent stem cells.
Quantitative PCR-based measurement of expression of Cd59, Best1, Rlbp1,
Pou5f1 and Lin28 transcript in a variety of cells. ACTB and HPRT were used
as housekeeping genes. Bars represent ± SD (n= 1–4). RPE SD RPE
derived by spontaneous differentiation, RPE DD RPE derived by directed
differentiation, fRPE foetal RPE, hESC human embryonic stem cell, hiPSC
human induced pluripotent stem cell, RPE retinal pigment epithelium
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about 6-fold level lower than that in RPE cells. However,
the expression of CD59 protein is negligible in stem cells
as demonstrated by our flow cytometry data. This high-
lights the importance of corroborating transcript levels
with protein expression because there may not necessarily
be a proportional relationship. In this context, our screen
using live, non-permeabilized cells allowed identification
of cell surface expressed proteins that were amenable to
cell sorting and separation-based applications. Further
work is also needed to understand the dynamics of CD59
protein expression during the differentiation time course.
This will help to clarify whether progenitors at intermedi-
ate stages of differentiation can be separated from mature
RPE, in addition to undifferentiated stem cells.
Conclusion
In summary, this study demonstrates the utility of a novel
sorting approach based on CD59 expression that may help
to ensure safety of pluripotent stem cell-derived RPE for
clinical applications as well as in generation of pure RPE
populations for research and in-vitro disease modelling.
This approach can also have utility for other stem cell-
derived cell types and their therapeutic use.
Additional files
Additional file 1: Figure S1. Showing a representative bright-field image
of typical morphology of cells used for screening for cell surface markers.
The cells form a monolayer and display cobblestone morphology typical of
RPE cells. Scale bar = 400 μm (10×) and 200 μm (20×). (TIF 8794 kb)
Additional file 2: Figure S2. Showing expression of indicated proteins
measured by flow cytometry in hESCs (left) and hESC-derived RPE (right).
x axis represents the log-fluorescence intensity, y axis represents relative
cell counts. (TIF 1923 kb)
Additional file 3: Figure S3. Showing expression of CD59 measured by
flow cytometry at days 0, 6, 9 and 45 of the differentiation time course.
x axis represents the log-fluorescence intensity, y axis represents relative
cell counts. (TIF 1704 kb)
Additional file 4: Figure S4. Showing expression of CD59 (top) and
TRA-1-60 (bottom) measured by flow cytometry in cell suspensions
created by mixing together different hESC-derived RPE and hESCs. x axis
represents the log-fluorescence intensity, y axis represents relative cell
counts. (TIF 2661 kb)
Additional file 5: Figure S5. Showing the CD59+ and CD59– samples
sorted in Fig. 3 re-analysed by flow cytometry to show the purity of the
individual fractions collected. The P4 gated events represent the CD59-positive
fraction and the P5 gated events represent the CD59-negative fraction.
(TIF 2445 kb)
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